drugset / Trial / NCT03764618
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to assess the efficacy of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).
Timeline
- Start
- 2019-04-24
- Primary completion
- 2022-04-11
- Completion
- 2022-04-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fostamatinib | Small molecule | 150 mg | Oral |